May 23rd, Cardiology Today, “Besides treating cancer, peptide receptor radionuclide therapy with radiolabeled somatostatin analogs may offer a novel approach to treating inflammation in the atherosclerotic plaques of patients with CVD, results from a new study suggest.”   “Since SSTR-2 receptors are also expressed in macrophages, we speculated that DOTATATE-PET/CT might be used to detect vulnerable plaques and that a [peptide receptor radionuclide therapy] procedure could reduce inflammation in the arterial wall,” Schatka said.